Michael J Astrue Net Worth

The estimated Net Worth of Michael J Astrue is at least $4.67 Thousand dollars as of 4 September 2013. Michael Astrue owns over 10,000 units of VIVUS stock worth over $4,665 and over the last 20 years Michael sold VVUS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Michael Astrue VVUS stock SEC Form 4 insiders trading

Michael has made over 2 trades of the VIVUS stock since 2005, according to the Form 4 filled with the SEC. Most recently Michael bought 10,000 units of VVUS stock worth $119,600 on 4 September 2013.

The largest trade Michael's ever made was buying 20,000 units of VIVUS stock on 20 May 2005 worth over $124,200. On average, Michael trades about 4,286 units every 433 days since 2005. As of 4 September 2013 Michael still owns at least 10,000 units of VIVUS stock.

You can see the complete history of Michael Astrue stock trades at the bottom of the page.

What's Michael Astrue's mailing address?

Michael's mailing address filed with the SEC is C/O TRANSKARYOTIC THERAPIES INC, 700 MAIN STREET, CAMBRIDGE, MA, 02139.

Insiders trading at VIVUS

Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner, and Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.

What does VIVUS do?

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Complete history of Michael Astrue stock trades at InVivo Therapeutics Corp and VIVUS

VIVUS executives and stock owners

VIVUS executives and other stock owners filed with the SEC include:

• John Amos,
  Chief Executive Officer, Director
• John Slebir,
  Senior Vice President - Business Development, General Counsel, Secretary
• Santosh Varghese,
  Senior Vice President, Chief Medical Officer
• Mark Oki,
  Chief Financial Officer, Senior Vice President, Chief Accounting Officer
• Thomas King,
  Independent Director
• David Norton,
  Independent Chairman of the Board
• Jill Frizzley,
  Independent Director
• Herman Rosenman,
  Independent Director
• Jorge Plutzky,
  Independent Director
• Edward Kangas,
  Independent Director
• Karen Ferrell,
  Independent Director
• Allan Shaw,
  Director
• Herm Rosenman,
  Director
• Eric W Roberts,
  Director
• Tide Capital, Llc North Tid...,
  
• Seth H. Z. Fischer,
  Chief Executive Officer
• Mayu Sris,
  Director
• Kenneth Suh,
  President
• Wesley Day,
  Vice President, Clinical
• Michael /Ny/ Miller,
  Chief Commercial Officer
• Wang Changjin,
  VP, Business Development
• Virgil A Place,
  Chairman & CSO
• Graham Strachan,
  Director
• Samuel F Colin,
  Director
• Ernest Mario,
  Director
• Anthony P. Zook,
  Chief Executive Officer
• John W Dietrich,
  Vice President, R & D
• Terry Nida,
  VP, Worldwide Marketing/
• Svai S Sanford,
  Interim CFO
• Mario M Rosati,
  Director
• Alexander J Denner,
  Director
• Jon C Biro,
  10% owner
• J Martin Carroll,
  Director
• Robert N Wilson,
  Director
• Alexander J Sarissa Capital...,
  
• M. Scott Oehrlein,
  Chief Operations Officer
• Timothy E Morris,
  VP, Finance and CFO
• Leland F Wilson,
  President & CEO
• Linda M Dairiki Shortliffe,
  Director
• Charles J Casamento,
  Director
• Lee Perry,
  Vice President & Chief
• Jacob Pieter Kastelein Joha...,
  Director
• Michael J Astrue,
  Director
• Mark B Logan,
  Director
• Michael Patrick Miller,
  SVP, Chief Commercial Officer
• Guy P Marsh,
  VP, Operations & General Mgr.
• Neil Gesundheit,
  VP, Chief Medical Officer
• Larry J Strauss,
  Vice President, Finance & CFO
• James R Nickel,
  Vice President, Clinical
• Peter Y Tam,
  VP, Business Planning
• Carol Zoltowski,
  Vice President, Regulatory
• Lori Forrest,
  VP, Operations & General Mgr.